Draegerwerk AG & Co. KGaA · XETR:DRW8
Draegerwerk AG & Co. KGaA — Drägerwerk AG & Co. KGaA — Q1 2015 Earnings Presentation
20 slides from Draegerwerk AG & Co. KGaA's earnings presentation, Apr 29, 2015
Slide 1: Conference call Interim report January 1 to March 31, 2015
Conference call Interim report January 1 to March 31, 2015 Lübeck, April 29, 2015
Slide 2: Disclaimer
Disclaimer This presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase any securities. No money, securities or other consideration is being solicited by this presentation. This presentation contains forward-looking statements regarding the future d
Slide 3: Business development Dräger Group
Business development Dräger Group Q1 2014 Q1 2015 Change € million € million % Order Intake 544.6 615.3 13.0 1 Net Sales 513.2 545.5 6.3 1 % growth -3.4% 6.3% % growth (currency adjusted) 1.0% -0.3% Gross Profit 240.0 257.8 7.4 Gross margin 46.8% 47.3% Functional Expenses -220.9 -253.2 -14.7 % of Ne
Slide 4: Changes in the reporting of the segments from Q1
Changes in the reporting of the segments from Q1 1. Complete allocation of net sales and expenses to customer segments medical / safety Decline in net sales in safety (relevant portion Allocation on the basis of customer/product (not as of intercompany sales). previously on the basis of legal entiti
Slide 5: Changes in the reporting of the segments from Q1
Changes in the reporting of the segments from Q1 Segment Safety: Elimination of Only minor effects on „Drägerwerk… / intercompany sales, e.g. net sales of medical Other Companies“ soda lime and sensors. division (only minor and group FY effect approx. intercompany sales) consolidation no EUR 35m lon
Slide 6: Business development Medical division: order entry in Q1 2015
Business development Medical division: order entry in Q1 2015 % nom % cc 402.5 +15.2% +7.7% Middle East, Africa & Others 42.6 +12.1% +2.0% +12.4% -1.9% 73.6 Asia/Pasific +24.2% +9.0% 80.1 Americas +13.7% +11.9% 206.1 Europe Q1 2015 6
Slide 7: Business development Medical division
Business development Medical division Net Sales Good order development in +0.3% Europe and Americas Currency (especially Central / South adjusted America). Slight increase in +7,4% nominal 354.3 demand from Middle East, 330.0 Africa & Others. Decline in Asia-Pacific. Q1‘14 Q1‘15 Good demand for Anes
Slide 8: Business development Safety division: order entry in Q1 2015
Business development Safety division: order entry in Q1 2015 % nom % cc Middle East, 212.8 +9.0% +3.4% Africa & Others 11.0 +8.6% +1.6% Asia/Pasific 30.5 +6.8% -5.4% +8.7% -6.4% 36.3 Americas +9.6% +8.2% 135.1 Europe Q1 2015 8
Slide 9: Business development Safety division
Business development Safety division Net Sales Good order development in -1.3% Europe. Slight increase in Currency demand from Middle East, adjusted Africa & Others. Decline in +4,4% nominal Asia-Pacific and Americas. 191.2 183.2 Strong order growth from Government Applications (i.e. Q1‘14 Q1‘15 imp
Slide 10: Key Figures
Key Figures Q1 2014 Q1 2015 Change € million € million % Cashflow from operating activities 25.1 -62.6 -349.2 Investments 20.1 91.3 353.4 1 Cash and cash equivalents 208.9 141.9 -32.0 1 Net financial debt 93.2 150.4 61.4 1 2 0.37 0.63 Net financial debt /EBITDA 1 Capital employed 1,045.4 1,269.7 21.
Slide 11: Outlook
Outlook 2014 2015e Mid term 2019e Net Sales + 4.0% 2.0% – 5.0% 3.0% – 6.0% (net of currency effects) (net of currency effects) (net of currency effects) EBIT margin 7.3% 6.0% – 8.0%* >10 %* Gross margin 46.7% On par with prior year Operating 105.0% > 70.0% cash flow of EBIT of EBIT Equity ratio 40.1
Slide 12: Questions & Answers
Questions & Answers Drager ee “e 12 Drager. Technik fiir das Leben®
Slide 13: Appendix
Appendix Drager 13
Slide 14: Business development Medical and Safety division
Business development Medical and Safety division Medical Division Q1 2014 Q1 2015 Change € million € million % Order Intake 349.3 402.5 15.2 1 Net Sales 330.0 354.3 7.4 1 EBIT 3.6 3.8 4.8 EBIT Margin 1.1% 1.1% DVA 47.6 37.4 -21.4 1 Currency adjusted 3 M: order intake +7,7%, net sales +0,3% Safety Di
Slide 15: Functional Expenses
Functional Expenses Q1 2014 Q1 2015 Change € million € million % R&D -50.3 -56.3 12.0 % of Net Sales -9.8% -10.3% SG&A -171.2 -197.1 15.1 % of Net Sales -33.4% -36.1% Functional Expenses total -220.9 -253.2 14.7 % of Net Sales -43.0% -46.4% 15
Slide 16: Consolidated balance sheet
Consolidated balance sheet Assets 31 Dec 2013 31 Dec 2014 Change € million € million % Intangible assets 283.0 294.2 4.0 Property, plant and equipment 310.8 349.9 12.6 Other non-current assets 123.4 137.3 11.2 Non-current assets 717.2 781.5 9.0 Inventories 372.3 388.5 4.4 Trade receivables 640.8 657
Slide 17: Consolidated balance sheet
Consolidated balance sheet Equity and liabilities 31 Dec 2013 31 Dec 2014 Change € million € million % Equity 816.0 896.6 9.9 Liabilities from participation certificates 20.0 20.9 4.3 Provisions for pensions and similar obligations 217.2 297.0 36.8 Non-current interest-bearing loans 252.3 168.6 -33.
Slide 18: Cash-flow statement
Cash-flow statement Q1 2014 Q1 2015 Change € million € million % Group net profit 8.5 -3.1 -136.8 Change in inventories -32.5 -56.2 -73.0 Change in accounts receivables 85.6 65.2 -23.9 Change in accounts payables -28.9 -34.6 -19.7 Depreciation and amortization 17.1 19.6 15.0 Other operating cash flo
Slide 19: Financial calendar
Financial calendar March 11, 2015 - Accounts press conference, Lübeck - Analysts meeting, Frankfurt April 29, 2015 - Report for the first three months 2015 - Conference call, Lübeck April 30, 2015 - Annual shareholders' meeting, Lübeck July 30, 2015 - Report for the first six months 2015 - Conferenc
Slide 20: Contact
Contact Melanie Kamann Thomas Fischler Corporate Communications Investor Relations Drägerwerk AG & Co. KGaA Drägerwerk AG & Co. KGaA Moislinger Allee 53−55 Moislinger Allee 53−55 23558 Lübeck, Germany 23558 Lübeck, Germany Tel +49 451 882-3998 Tel +49 451 882-2685 Fax +49 451 882-3944 Fax +49 451 88
Drägerwerk AG & Co. KGaA — Q1 2015 Earnings Presentation on 6ix